Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-β

Journal of Neuroimmunology

Volumn 133, Issue 1-2, 2002, Pages 217-224

  Killestein, J ^a   Hintzen, R Q ^b   Uitdehaag, B M J ^a   Baars, P A ^c   Roos, M T ^c   Van Lier, R A W ^c   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

CD2; CD28; Interferon ; Multiple sclerosis; PHA; T cell proliferation

Indexed keywords

BETA INTERFERON; CD2 ANTIGEN; CD28 ANTIGEN; PHYTOHEMAGGLUTININ; STEROID;

ADULT; AGED; ARTICLE; BLOOD; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; T LYMPHOCYTE;

ADULT; AGE FACTORS; CELL DIVISION; DRUG RESISTANCE; FEMALE; HUMANS; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; SEX FACTORS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0036890956     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00373-9     Document Type: Article

References (43)

1. Antel J.P., Bania M.B., Reder A., Cashman N. Activated suppressor cell dysfunction in progressive multiple sclerosis. J. Immunol. 137(1):1986;137-141.
2. Bloemena E., Roos M.T., Van Heijst J.L., Vossen J.M., Schellekens P.T. Whole-blood lymphocyte cultures. J. Immunol. Methods. 122(2):1989;161-167.
3. Boxel-Dezaire A.H., Trigt-Hoff S.C., Killestein J., Schrijver H.M., van Houwelingen J.C., Polman C.H., Nagelkerken L. Contrasting responses to interferon-β-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann. Neurol. 48(3):2000;313-322.
4. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., Hartung H., Seeldrayers P., Sorensen P.S., Rovaris M., Martinelli V., Hommes O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 357(9268):2001;1576-1582.
5. Compston A., Coles A. Multiple sclerosis. Lancet. 359(9313):2002;1221-1231.
6. Coyle P.K., Hartung H.P. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult. Scler. 8(1):2002;2-9.
7. de Jong R., Brouwer M., Miedema F., van Lier R.A. Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. J. Immunol. 146(7):1991;2088-2094.
8. Douziech N., Seres I., Larbi A., Szikszay E., Roy P.M., Arcand M., Dupuis G., Fulop T. Jr. Modulation of human lymphocyte proliferative response with aging. Exp. Gerontol. 37(2-3):2002;369-387.
9. European Study Group on interferon-β-1b in secondary progressive MS Placebo-controlled multicentre randomised trial of interferon-β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352(9139):1998;1491-1497.
10. Froebel K.S., Pakker N.G., Aiuti F., Bofill M., Choremi-Papadopoulou H., Economidou J., Rabian C., Roos M.T., Ryder L.P., Miedema F., Raab G.M. Standardisation and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. European Concerted Action on Immunological and Virological Markers of HIV Disease progression. J. Immunol. Methods. 227(1-2):1999;85-97.
11. Gerli R., Bertotto A., Agea E., Lanfrancone L., Cernetti C., Spinozzi F., Rambotti P. Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjogren's syndrome. J. Clin. Invest. 86(6):1990;1870-1877.
12. Hafler D.A., Buchsbaum M., Weiner H.L. Decreased autologous mixed lymphocyte reaction in multiple sclerosis. J. Neuroimmunol. 9(6):1985;339-347.
13. Hirsch R.L. Defective autologous mixed lymphocyte reactivity in multiple sclerosis. Clin. Exp. Immunol. 64(1):1986;107-113.
14. Horwitz D.A., Tang F.L., Stimmler M.M., Oki A., Gray J.D. Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cell-accessory cell interaction. Arthritis Rheum. 40(5):1997;822-833.
15. IFN-β Multiple Sclerosis Study Group Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43(4):1993;655-661.
16. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E. III, Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39(3):1996;285-294.
17. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343(13):2000;898-904.
18. Khoury S.J., Guttmann C.R., Orav E.J., Kikinis R., Jolesz F.A., Weiner H.L. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch. Neurol. 57(8):2000;1183-1189.
19. Killestein J., Den Drijver B.F., Van der Graaff W.L., Uitdehaag B.M., Polman C.H., van Lier R.A. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult. Scler. 7(3):2001;145-150.
20. Lucchinetti C.F., Bruck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6(3):1996;259-274.
21. Lucchinetti C., Bruck W., Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr. Opin. Neurol. 14(3):2001;259-269.
22. McDonnell G.V., McMillan S.A., Douglas J.P., Droogan A.G., Hawkins S.A. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease. J. Neurol. 246(2):1999;87-92.
23. Noronha A., Toscas A., Jensen M.A. Interferon-β decreases T cell activation and interferon-γ production in multiple sclerosis. J. Neuroimmunol. 46(1-2):1993;145-153.
24. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343(13):2000;938-952.
25. Paty D.W., Li D.K. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 43(4):1993;662-667.
26. Polman C.H., Miller D.H., McDonald W.I., Thompson A.J. Treatment recommendations for interferon-β in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 67(5):1999;561-564.
27. Prat A., Pelletier D., Duquette P., Arnold D.L., Antel J.P. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann. Neurol. 47(2):2000;234-237.
28. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of interferon-β-1a in relapsing/remitting multiple sclerosis. Lancet. 352(9139):1998;1498-1504.
29. Reder A.T., Antel J.P. Injecting rationale into interferon-β therapy. Neurology. 54(11):2000;2034-2035.
30. Reder A.T., Arnason B.G., Maimone D., Rohwer-Nutter D. The function of the CD2 protein is abnormal in multiple sclerosis. J. Autoimmun. 4(3):1991;479-491.
31. Rep M.H., Hintzen R.Q., Polman C.H., van Lier R.A. Functional defects in peripheral blood T cells of multiple sclerosis patients. Diminished in vitro responsiveness in accessory cell dependent activation systems. J. Neuroimmunol. 52(2):1994;139-146.
32. Rep M.H., Hintzen R.Q., Polman C.H., van Lier R.A. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67(2):1996;111-118.
33. Rep M.H., Schrijver H.M., van Lopik T., Hintzen R.Q., Roos M.T., Ader H.J., Polman C.H., van Lier R.A. Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J. Neuroimmunol. 96(1):1999;92-100.
34. Revesz T., Kidd D., Thompson A.J., Barnard R.O., McDonald W.I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117(Pt. 4):1994;759-765.
35. Roos M.T., Prins M., Koot M., de Wolf F., Bakker M., Coutinho R.A., Miedema F., Schellekens P.T. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS. 12(14):1998;1745-1751.
36. Rudick R.A., Carpenter C.S., Cookfair D.L., Tuohy V.K., Ransohoff R.M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-β Neurology. 43(10):1993;2080-2087.
37. Schellekens P.T., Roos M.T., de Wolf F., Lange J.M., Miedema F. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J. Clin. Immunol. 10(2):1990;121-127.
38. Schindowski K., Frohlich L., Maurer K., Muller W.E., Eckert A. Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets. Mech. Ageing Dev. 123(4):2002;375-390.
39. Stio M., Treves C., Celli A., Tarantino O., d'Albasio G., Bonanomi A.G. Synergistic inhibitory effect of cyclosporin A and vitamin D derivatives on T-lymphocyte proliferation in active ulcerative colitis. Am. J. Gastroenterol. 97(3):2002;679-689.
40. Thompson A.J., Polman C.H., Miller D.H., McDonald W.I., Brochet B., Filippi M., Montalban X., De Sa J. Primary progressive multiple sclerosis. Brain. 120(Pt. 6):1997;1085-1096.
41. Thompson A.J., Montalban X., Barkhof F., Brochet B., Filippi M., Miller D.H., Polman C.H., Stevenson V.L., McDonald W.I. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 47(6):2000;831-835.
42. van Kemenade F.J., Tellegen E., Maurice M.M., Lankester A.C., Kuijpers T.W., Brouwer M., de Jong R., Miedema F., van Lier R.A. Simultaneous regulation of CD2 adhesion and signaling functions by a novel CD2 monoclonal antibody. J. Immunol. 152(9):1994;4425-4432.
43. van Lier R.A., Brouwer M., Aarden L.A. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur. J. Immunol. 18(1):1988;167-172.